contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


alligator-bioscience-to-participate-in-upcoming-scientific-and-industry-conferences-in-january-and-february-2023

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Alligator Bioscience är ett forskningsbaserat bioteknikbolag. Bolaget använder en patenterad teknologi för att utveckla biologiska läkemedelskandidater inom inflammation och cancer, och är verksamt i den tidigare delen av läkemedelsutvecklingskedjan. Alligator Bioscience har en global teknologiplattform och är aktivt inom segmentet proteinläkemedel. Bolaget grundades år 2001 och har sitt huvudkontor i Lund.

Alligator Bioscience

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following conferences during January and February 2023...

<div class="mfn-preamble">Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following conferences during January and February 2023:</div><div class="mfn-body"><ul><li>Redeye Fight Cancer Day 2023, January 19, Stockholm Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.</li></ul><ul><li>Aktiespararna "Aktiedagen i Lund", January 31, Lund Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.</li></ul><ul><li>ØU Life Science Investor Conference, February 22, Copenhagen, Denmark Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.</li></ul><ul><li>European Bispecific &amp; Multispecific Antibody Congress, February 22 - 23, Amsterdam, Netherlands Laura von Schantz, Vice President of Discovery at Alligator Bioscience, will give a presentation entitled "Reviewing the Landscape of Obligate MoAs for Bi-/Multispecifics to Prioritise and De-Risk Current and Future Efforts" at 2.30 pm CET on February 22. Registration for the conference is open <a rel="nofollow noopener" href="https://multispecificseu.com/events/european-bispecific-multispecific-antibody-congress#register">here</a>.</li></ul> The information was submitted for publication, through the agency of the contact persons set out below, at 8:00 a.m. CET on January 9, 2023.</div><div class="mfn-footer mfn-contacts mfn-127b8acc461b">For further information, please contact:<hr>Søren Bregenholt, CEO E-mail:&nbsp;<a rel="nofollow noopener" href="mailto:sbr@alligatorbioscience.com?subject=Alligator%20Bioscience%20to%20Present%20Additional%20data%20of%20ATOR-1017%20First-in-Human%20Study%20via%20poster%20presentation%20at%20ASCO%20Annual%20Meeting%202022">soren.bregenholt@alligatorbioscience.com</a> Phone: +46 (0) 46 540 82 00LifeSci Advisors Investor Relations Guillaume van Renterghem E-mail:&nbsp;<a rel="nofollow noopener" href="mailto:gvanrenterghem@lifesciadvisors.com?subject=Alligator%20Bioscience%20to%20Present%20Additional%20data%20of%20ATOR-1017%20First-in-Human%20Study%20via%20poster%20presentation%20at%20ASCO%20Annual%20Meeting%202022">gvanrenterghem@lifesciadvisors.com</a> Phone: +41 (0) 76 735 01 31</div><div class="mfn-footer mfn-about mfn-76021e509ec4">About Alligator Bioscience<hr>Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.For more information, please visit <a rel="nofollow noopener" href="https://www.alligatorbioscience.se/en">alligatorbioscience.com</a>.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="nofollow noopener" href="https://storage.mfn.se/c3e53a1b-5cc7-4443-ae1e-09eb89eed4e4/alligator-bioscience-to-participate-in-upcoming-scientific-and-industry-conferences-in-january-and-february-2023.pdf" class="mfn-generated mfn-primary">Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023</a></div>

Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023